A randomized, multicenter, open-label phase 3 LITESPARK-033 study is designed to evaluate the efficacy and safety of belzutifan plus zanzalintinib versus cabozantinib in participants with advanced clear cell RCC who experienced recurrence during or after anti–PD-(L)1 adjuvant therapy.
T. Choueiri, T. Powles, M. Voss et al.· The Oncologist· 0 citations
Abstract Background For patients with advanced or metastatic clear cell renal cell carcinoma (ccRCC) who have relapsed after anti-programmed death protein 1 (anti–PD-1) or anti-programmed death ligand-1 (anti–PD-L1) treatment, second-line treatment options remain limited, consisting primarily of tyrosine kinase inhibit...
T. Choueiri, S. Pal, R. McKay et al.· The Oncologist· 0 citations
Abstract Background Nivolumab plus ipilimumab (NIVO+IPI) combination therapy is a first-line standard in metastatic renal cell carcinoma (mRCC). Despite durable responses in some patients, over 20% develop primary progressive disease (PPD) at first restaging imaging. In this study, we evaluated clinical factors associa...
É. Ibrahim, Wan-Ling Xie, R. El Hajj Chehade et al.· The Oncologist· 0 citations
Abstract Background Chromophobe renal cell carcinoma (ChRCC) is traditionally defined by its unique metabolic reprogramming, including an increase in mitochondrial mass. The mitochondrial plasma proteome of metastatic ChRCC has been recently reported (Steiner et al. Cancers 2026), and we defined a two-protein signature...
Tie-Gang Han, Clara Steiner, Steven Safi et al.· The Oncologist· 0 citations
Abstract Background Clear cell renal cell carcinoma (ccRCC) with sarcomatoid differentiation (sRCC) is associated with poor survival. Recent studies have shown downregulation of hypoxia-related pathways in sRCC (Motzer et al., Cancer Cell, 2020; El Zarif, Semaan et al., Cell Reports, 2024). In this study, we sought to...
R. Nawfal, É. Ibrahim, K. Semaan et al.· The Oncologist· 0 citations
Abstract Background Hypoxia signaling is a key driver of renal cell carcinoma (RCC) and is mediated by HIF-dependent transcription. ARNT (HIF-1β) is an essential HIF binding partner, but its expression and clinical relevance in RCC are poorly defined. With ARNT inhibitors in development, characterizing ARNT expression...
Yu-Wei Chen, S. Nazari, A. Elliott et al.· The Oncologist· 0 citations
Across three cohorts, higher ARNT expression correlated with higher BHS, and a consistent correlation was observed between ARNT and EPAS1 and HIF1A expressions, and a consistent correlation was observed between ARNT and EPAS1 expressions.
Wassim Daoud Khatoun, Ali Hajj Ali, Eddy Saad et al.· The Oncologist· 0 citations
An in vitro RCC antigen model system was established to evaluate the impact of belzutifan on T-cell cytotoxicity and revealed that IL-2 and IFNG were among the most significantly downregulated genes in HIF2α knockout T cells.
S. Kashima, Katrine N. Madsen, H. Soulati et al.· The Oncologist· 0 citations
Renal cell carcinomas (RCC) comprise multiple molecularly distinct cancers but most are treated empirically with therapies designed for clear cell RCC (ccRCC), the most common subtype, due to incomplete understanding of subtype-specific biology. We analyzed single-cell transcriptomes and chromatin accessibility profile...
Prathyusha Konda, Alexandra J. Wakolbinger, Yan-Tong Cui et al.· Nature Communications· 0 citations
A tissue residency gene program in Tex cells associated with non-response to immunotherapy was identified and nominates resident memory exhausted CD8+ T cells as a targetable subset of cells to improve CD8+ T cell-mediated anti-tumor immunity.
Rishabh Rout, S. Kashima, M. Hugaboom et al.· The Oncologist· 0 citations
The findings suggest an ECM–CD44 axis linking tumor mesenchymal programs to M2-like polarization and increased macrophage infiltration in stromal and sarcomatoid areas compared to clear cell regions.
Katsuhiro Ito, S. Kashima, Rishabh Rout et al.· The Oncologist· 0 citations
It is found that baseline tumor infiltration by exhausted T cells with a resident memory phenotype (Tex-rm) is significantly associated with worse PFS in advanced RCC patients receiving ICI monotherapy or ICI+TKI combination therapy.
Zhao-Chen Ye, S. Kashima, Rishabh Rout et al.· The Oncologist· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
